Jaguar Health Secures $350K in Short-Term Notes and Warrants for Working Capital
JAGX is trading near its 52-week low of $0.855 (3.8% above the low) on elevated volume (43× avg).
Summary
Jaguar Health, Inc. amended a previous 8-K to correct dates related to a $350,000 unsecured promissory note and warrants for 350,000 shares, with proceeds allocated for working capital.
Key Events · Financing and Capital Events · JAGX
-
Secured Short-Term Financing
Jaguar Health, Inc. entered into securities purchase agreements for $350,000 aggregate principal amount of unsecured promissory notes, maturing in one month.
-
Issued Warrants for Future Equity
Investors also received warrants to purchase up to 350,000 shares of common stock at an exercise price of $1.00 per share, exercisable immediately.
-
Capital for Working Capital
Proceeds from the notes will be used for working capital and general corporate purposes.
-
Amendment to Correct Dates
This 8-K/A corrects scrivener's errors in the original filing regarding the execution and closing dates of the agreements, now confirmed as January 6, 2026.
Analysis · JAGX · Life Sciences
This amended 8-K clarifies the execution and closing dates of a recent financing agreement. The underlying transaction involves Jaguar Health securing $350,000 through unsecured promissory notes, which mature in a very short one-month period. Additionally, investors received warrants to purchase 350,000 shares at an exercise price of $1.00, a premium to the current stock price. While the capital infusion is crucial for working capital, the short maturity of the notes indicates immediate financial needs and could pose a refinancing challenge soon. The premium pricing of the warrants, however, suggests some investor confidence in the company's future value.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.6% of the 1568 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.86 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.